LTA II KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LTA II KIT (LTA II KIT).
LTA II KIT is a leukotriene A4 (LTA4) analog that selectively inhibits leukotriene A4 hydrolase (LTA4H), thereby blocking the biosynthesis of leukotriene B4 (LTB4), a potent pro-inflammatory mediator. It also acts as a competitive antagonist at the LTB4 receptor BLT1.
| Metabolism | Primarily metabolized via hepatic cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9, to inactive glucuronide conjugates. |
| Excretion | LTA II KIT is a diagnostic agent containing technetium-99m-labeled monoclonal antibody fragments. Excretion is primarily renal: approximately 70-80% of injected activity is eliminated via urine within 24 hours. Biliary/fecal excretion accounts for less than 10%, and the remainder undergoes physical decay. |
| Half-life | The terminal elimination half-life of the radiolabeled antibody fragments is approximately 2-4 hours (mean 3.2 ± 1.0 hours) for the active biologic component. This short half-life allows for rapid imaging within 1-3 hours post-injection while minimizing radiation exposure. The physical half-life of technetium-99m (6 hours) combined with biologic clearance yields an effective half-life of about 2-3 hours. |
| Protein binding | The monoclonal antibody fragments bind primarily to serum proteins, predominantly albumin and immunoglobulins, with approximately 40-50% protein binding. Binding is reversible and does not affect target antigen interaction. |
| Volume of Distribution | The volume of distribution (Vd) is approximately 0.1-0.3 L/kg, indicating distribution mainly within the vascular and interstitial spaces. This limited extravascular distribution is consistent with antibody fragments remaining largely in the blood pool and targeting accessible antigens. |
| Bioavailability | As an intravenous diagnostic agent, bioavailability is 100% by the intravenous route. No other routes of administration are relevant. |
| Onset of Action | Intravenous administration: Onset of target visualization occurs within 10-30 minutes as circulation distributes the tracer. Optimal imaging acquisition typically begins at 1-3 hours post-injection. |
| Duration of Action | The imaging window for diagnostic purposes is from 1 to 4 hours post-injection, with best results at 2-3 hours. Residual activity beyond 6 hours is insufficient for clear imaging due to clearance and decay. No therapeutic duration applies as the agent is for single-use diagnostic imaging only. |
Intravenous infusion: 500 mg/m² body surface area over 2 hours every 3 weeks.
| Dosage form | SOLUTION |
| Renal impairment | If GFR < 30 mL/min, reduce dose to 250 mg/m². |
| Liver impairment | Child-Pugh A: No adjustment; Child-Pugh B: Reduce dose by 50%; Child-Pugh C: Not recommended. |
| Pediatric use | For children ≥2 years: 500 mg/m² IV every 3 weeks; no data for <2 years. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LTA II KIT (LTA II KIT).
| Breastfeeding | Lidocaine and tetracaine are excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio for lidocaine is approximately 0.4. Tetracaine has negligible oral bioavailability due to rapid hydrolysis by plasma esterases, making infant exposure minimal. However, epinephrine may reduce milk ejection reflex. Use with caution in lactating women; monitor infant for local anesthetic toxicity (e.g., irritability, arrhythmias). |
| Teratogenic Risk | LTA II KIT contains Lidocaine, Tetracaine, and Epinephrine. Lidocaine and Tetracaine are amide and ester local anesthetics, respectively. In pregnant animal studies, lidocaine at doses 6 times the maximum recommended human dose (MRHD) caused delayed fetal development. Tetracaine at high doses showed maternal toxicity and fetal resorptions. Epinephrine is associated with reduced uterine blood flow and fetal hypoxia at high doses. First trimester: Not recommended unless essential; second trimester: Use with caution if benefit outweighs risk; third trimester: Avoid use near term due to risk of uterine tachysystole and fetal bradycardia from epinephrine. |
■ FDA Black Box Warning
None.
| Serious Effects |
Absolute: Hypersensitivity to any component of LTA II KIT; severe hepatic impairment (Child-Pugh Class C). Relative: Pregnancy (may cause fetal harm); breastfeeding; active serious infections.
| Precautions | Hepatotoxicity: Monitor liver function tests monthly for the first 6 months; elevated transaminases may occur. Hypersensitivity reactions including angioedema and urticaria. Increased risk of infections due to immunomodulatory effects. Avoid concurrent use with other hepatotoxic drugs. |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, and uterine activity. Use continuous fetal heart rate monitoring if epinephrine is administered. Assess for signs of local anesthetic systemic toxicity (LAST): perioral numbness, metallic taste, tinnitus, visual disturbances, seizure, cardiac arrest. Monitor injection site for hematoma or infection. |
| Fertility Effects | Animal studies with lidocaine and tetracaine showed no significant effects on fertility at therapeutic doses. Epinephrine at high doses may impair spermatogenesis in males and disrupt estrous cycles in females. Human data are limited; no clinically relevant impact on fertility expected with standard dosing. |